1. Aschenbrenner, Diane S. MS, RN


* For the first time, a drug, tesamorelin (Egrifta), has been approved to treat HIV therapy-related lypodystrophy.


* Tesamorelin decreases abdominal fat, but it's not yet known whether the drug decreases the risk of cardiovascular disease or increases compliance with HIV therapy.


* Tesamorelin may cause significant changes in blood glucose levels, among other adverse effects.